Effect of the nitrosourea anti-tumor chemotherapeutical agent MCNU on five human myeloma cell lines.

Abstract

We investigated the effects of MCNU (methyl-6)3-(2-chloroethyl)-3-nitrosoureido)-6-deoxy- alpha-D-glucopyranoside), a nitrosourea anti-tumor agent developed in Japan, on cell growth and differentiation in five human myeloma cell lines and compared it with relative expression levels of MDR-1 gene. Although 10 microg/ml of MCNU inhibited cell growth in KMM-1 and KMS-5 lines, other three cell lines required 20-40 microg/ml of MCNU to obtain similar growth inhibition. Accumulation up to the G2 phase of the cell cycle was observed in KMM-1 and KMS-5 lines and the cloning efficiency of KMS-5 cells was reduced by MCNU. On the other hand, expression of surface markers on these lines was not altered remarkably except for increased expression of CD38 on KMS-5 cells. However, the effect of MCNU on these cell lines did not correlate to relative expression levels of MDR-1 gene analyzed by RT-PCR. MCNU may inhibit the growth of myeloma cells by the accumulation of these cells up to the G2 phase, but may not affect their differentiation.

• Authors: T Otsuki, H Sakaguchi, O Yamada, Y Yawata, A Ueki
• Journal: Oncology reports (Oncol Rep) 1998 Jul-Aug Vol. 5 Issue 4 Pg. 827-32 ISSN: 1021-335X [Print] Greece
• PMID: 9625826 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Biomarkers, Tumor
• Nitrosourea Compounds
• ranimustine

Topics

• Antineoplastic Agents (therapeutic use)
• Biomarkers, Tumor
• Cell Cycle (drug effects)
• Cell Differentiation (drug effects)
• Cell Division (drug effects)
• Drug Screening Assays, Antitumor
• Gene Expression Regulation, Neoplastic (drug effects)
• Genes, MDR
• Humans
• Multiple Myeloma (drug therapy, metabolism, pathology)
• Nitrosourea Compounds (therapeutic use)
• Tumor Cells, Cultured